Afraxis to participate in NIHs Therapeutics for Rare and Neglected Disease Program Afraxis.

‘TRND collaborates with researchers and companies with an aim of translating promising molecules into potential new drugs for uncommon and neglected illnesses,’ said NHGRI’s John McKew PhD, Chief of TRND’s Therapeutic Advancement Branch. ‘This is a hard phase of drug development connected with high failure prices for just about any molecule. The outcome can be uncertain.’.. Afraxis to participate in NIH’s Therapeutics for Rare and Neglected Disease Program Afraxis, a San Diego-based biotechnology business developing drugs to treat rare genetic illnesses through the modulation of p21-activated kinase , announced today that it’s been selected to participate in the National Institutes of Health’s Therapeutics for Rare and Neglected Disease Program.NewYork-Presbyterian Hospital/Weill Cornell INFIRMARY, located in New York City, is among the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and its educational partner, Weill Cornell Medical University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in every certain specific areas of medicine, and is focused on excellence in patient treatment, research, education and community service. NewYork-Presbyterian, which can be ranked sixth on the U.S.News & World Report’s set of top hospitals, also comprises NewYork-Presbyterian Medical center/Columbia University INFIRMARY.

ASBMB honors UMMS professor with 2011 William C. Rose Award The American Culture for Biochemistry and Molecular Biology has named Melissa J.